N4 Pharma (N4P) Share Price, News & Analysis

Company Overview

N4 Pharma Plc, a specialist pharmaceutical company, develops silica nanoparticle delivery system for pharmaceutical and biotechnology companies in the United Kingdom. It develops Nuvec, a non-viral adjuvant delivery system for vaccines and cancer treatments. N4 Pharma Plc was incorporated in 1979 and is based in London, the United Kingdom.

Key Stats

• Today's Range: 0.50 to 0.60
• 50-Day Range: 0.40 to 0.65
• 52-Week Range: N/A
• Volume: 3.78 million shs
• Average Volume: 1.07 million shs
• Market Capitalization: £2.27 million
• P/E Ratio: N/A
• Dividend Yield: 3.12%
• Price Target: N/A
• Consensus Rating: N/A

N4P Stock Analysis - Frequently Asked Questions

How have N4P shares performed this year?

N4 Pharma's stock was trading at GBX 0.85 on January 1st, 2024. Since then, N4P stock has decreased by 32.4% and is now trading at GBX 0.58.
View the best growth stocks for 2024 here.

How were N4 Pharma's earnings last quarter?

N4 Pharma Plc (LON:N4P) released its quarterly earnings results on Thursday, September, 17th. The company reported ($0.48) earnings per share for the quarter.

How do I buy shares of N4 Pharma?

Shares of N4P stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of N4 Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that N4 Pharma investors own include Intercede Group (IGP), Medpace (MEDP), Regeneron Pharmaceuticals (REGN), Sirius Minerals (SXX), SolGold (SOLG), Reach (RCH) and Petra Diamonds (PDL).

Company Calendar

• Last Earnings: 9/17/2020
• Today: 9/18/2024

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: LON:N4P
• CUSIP: N/A
• CIK: N/A
• Web: www.n4pharma.com
• Phone: +44-1332-690061
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): GBX (0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: £-1,270,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -77.81%
• Return on Assets: -51.74%

Debt

• Debt-to-Equity Ratio: 1.62
• Current Ratio: 14.86
• Quick Ratio: 7.28

Sales & Book Value

• Annual Sales: £23,524.00
• Price / Sales: 83.91
• Cash Flow: GBX 0.22 per share
• Price / Cash Flow: 2.25
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 394,780,000
• Free Float: N/A
• Market Cap: £1.97 million
• Optionable: Not Optionable
• Beta: -0.37